The coverage of human papillomavirus vaccination in the Algarve region exceeds 90%, the Regional Health Administration of Algarve (ARS) said today, which welcomes the "good adhesion" of girls and their families.
Currently, the vaccination rates reached are about 90% for the first dose and 80% to 85% for the second dose.
On the occasion of the 10th anniversary of the integration of vaccination against human papillomavirus (HPV) in the National Vaccine Program, signed by the Directorate General for Health on 5 November, Marcelo Rebelo de Sousa, President of the Republic, the work that has been done in the last ten years were developed by healthcare professionals, it was emphasized and praiseworthy, "without which it would not be possible to achieve these results".
Vaccination against human papillomavirus, responsible for one of the most common sexually transmitted infections worldwide, began in October 2008 by administering three doses of 13 year old girls.
The vaccine is specifically designed to prevent precancerous lesions and cervical cancer, as well as vulva, vagina and anus. It also prevents genital warts associated with the genotype contained in the vaccine.
Cervical cancer is the second most common type of cancer in women, and in nearly 100% cases it is associated with pre-infection with papilloma virus.
The national campaign for the vaccination of girls born in 1992, 1993 and 1994 was initiated at the same time in January 2009 and was vaccinated in 2009, 2010 and 2011.
The vaccine used is a quadrivalent vaccine (HPV4), which provides protection against four serotypes of the virus, two of which are most closely related to cervical cancer.
In 2014, HPV vaccine was recommended under the National Vaccination Program (PNV) for girls aged 10 to 13 and in two dosing regimens.
However, technological development made it possible to place the non-invasive HPV vaccine (HPV9) on the market, which provided protection against nine serotypes of the virus, which increased the protection of about 90% of human papilloma virus types associated with the cervix and other anogenital cancer.
The HPV9 vaccine was introduced in 2017 into PNV for giving to girls for 10 years to optimize their level of protection.
Vaccination against human papillomavirus and the regular examination of cervical cancer in all women allows early prevention and intervention in the development of cervical cancer.
Over the past ten years, 750,000 girls have been vaccinated in Portugal, and Portugal has been ranked among the best in the case of vaccination against human papillomavirus according to the ARS.